AbstractBackgroundGastroparesis is a disorder characterized by delayed gastric emptying due to chronic abnormal gastric motility. The treatment of the disease often entails the co‐administration of several classes of pharmacological agents. These agents may be metabolized via the same pathway. Inhibition or induction of a shared metabolic pathway leads to change in the systemic levels of prescribed drugs, possibly leading to undesired clinical outcomes.PurposeThis review discusses different pharmacological treatment for gastroparesis patients and describes the potential for drug‐drug interactions (DDIs) in some of the combinations that are currently used. Prokinetic agents such as metoclopramide and domperidone are the cornerstone in treatment of gastroparesis. Antiemetic agents such as promethazine and ondansetron are frequently administered to gastroparesis patients to reduce nausea and vomiting. Gastroparesis is prevalent in diabetic patients and therefore antidiabetic agents are also prescribed. Many of these co‐administered drugs are metabolizedviacommon drug metabolizing enzymes and this can trigger potentialDDIs. The scientific literature was reviewed from the years 1975–2014 for original research articles and reviews that evaluatedDDIs in gastroparesis. Many commonly prescribed combinations were predicted to cause potentialDDIs in gastroparesis patients. This review will help inform about potential hazardous combinations. This information will hopefully lead to less adverse effects and more successful gastroparesis management.